Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery

Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus , whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus , however the...

Full description

Saved in:
Bibliographic Details
Published in:NPJ ANTIMICROBIALS AND RESISTANCE 2024-11, Vol.2 (1), p.38-12, Article 38
Main Authors: Baker, Emily, J., Allcott, Gemma, Cox, Jonathan A. G.
Format: Article
Language:English
Subjects:
631/326/22/1290
631/326/2565/107
Adenosine
Antibiotics
Antimicrobial agents
Biomedical and Life Sciences
Cystic fibrosis
Drug development
Drug discovery
Drug resistance
Infections
Life Sciences
Microbiology
Microorganisms
Mutation
Mycobacterium abscessus
Pathogens
Patients
Permeability
Physiology
Proteins
Review
Review Article
Ribonucleic acid
RNA
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus , whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus , however the methods used within antibiotic discovery are typically monomicrobial. This review will discuss this pathogen whilst considering the CF polymicrobial environment, to highlight future perspectives to improve M. abscessus drug discovery.
ISSN:2731-8745
2731-8745
DOI:10.1038/s44259-024-00060-5